[ad_1]

When most people hear about predicting heart disease, they think of cholesterol levels. Cholesterol is a major cause of heart disease, but a recent study from Brigham and Women’s Hospital, a founding member of Massachusetts General Brigham, shows that the glycan biomarker of IgG is also an important predictor of cardiovascular disease (CVD). It turned out to be. Researchers studied the glycocalyx of antibodies known as immunoglobulin G (IgG), which are involved in immune responses associated with chronic inflammation, in participants in two case-control studies. The results of this study may provide another biomarker to identify CVD risk and lead to earlier diagnosis of heart disease and stroke. CVD worsens over time, so early diagnosis is critical for better patient outcomes. The research team found that the glycocalyx on IgG was directly related to his risk of CVD events, possibly through inflammatory effects, and that her IgG glycocalyx score predicted future cardiovascular events independent of other risk factors. I discovered that.

IgG N-glycans, the glycocalyx that modifies IgG immunoglobulins, represent not only new biomarkers of cardiometabolic health but also potential targets for new drugs. Our results demonstrate a promising but underappreciated novel biomarker with great potential for risk stratification, CVD prevention, diagnostic, and therapeutic purposes. ”


Dr. Samia Mora, MHS, Brighams Division of Preventive Cardiovascular Medicine

sauce:

Brigham and Women’s Hospital

Reference magazines:

Hoshi, RA, other. (2024). N – Immunoglobulin G glycosylation profile and future cardiovascular events. circulation research. doi.org/10.1161/circresaha.123.323623.

[ad_2]

Source link